Cargando…

Carbapenem-Resistant Klebsiella pneumoniae in COVID-19 Era—Challenges and Solutions

The COVID-19 era brought about new medical challenges, which, together with nosocomial bacterial infections, resulted in an enormous burden for the healthcare system. One of the most alarming nosocomial threats was carbapenem-resistant Klebsiella pneumoniae (CRKP). Monitoring CRKP incidence and anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Ficik, Jozef, Andrezál, Michal, Drahovská, Hana, Böhmer, Miroslav, Szemes, Tomáš, Liptáková, Adriána, Slobodníková, Lívia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451955/
https://www.ncbi.nlm.nih.gov/pubmed/37627705
http://dx.doi.org/10.3390/antibiotics12081285
_version_ 1785095547196014592
author Ficik, Jozef
Andrezál, Michal
Drahovská, Hana
Böhmer, Miroslav
Szemes, Tomáš
Liptáková, Adriána
Slobodníková, Lívia
author_facet Ficik, Jozef
Andrezál, Michal
Drahovská, Hana
Böhmer, Miroslav
Szemes, Tomáš
Liptáková, Adriána
Slobodníková, Lívia
author_sort Ficik, Jozef
collection PubMed
description The COVID-19 era brought about new medical challenges, which, together with nosocomial bacterial infections, resulted in an enormous burden for the healthcare system. One of the most alarming nosocomial threats was carbapenem-resistant Klebsiella pneumoniae (CRKP). Monitoring CRKP incidence and antimicrobial resistance globally and locally is vitally important. In a retrospective study, the incidence of CRKP in the pre-COVID-19 period (2017–2019) and the COVID-19 pandemic (2020–2022) was investigated in the Central Military Hospital in Ružomberok, Slovak Republic. The relative incidence of CRKP significantly increased during the COVID-19 period—by 4.8 times, from 0.18 to 0.76%. At the same time, 47% of CRKP-positive patients also had COVID-19. Twenty-six KPC and sixty-nine NDM-producing isolates were identified. CRKPs isolated in the year 2022 were submitted to whole genome sequencing, and their susceptibility was tested to cefiderocol, ceftazidime–avibactam, imipenem–relebactam and meropenem–vaborbactam, with excellent results. KPC-producing isolates were also highly susceptible to colistin (92%). The NDM isolates revealed lower susceptibility rates, including only 57% colistin susceptibility. ST-307 prevailed in KPC and ST-11 in NDM isolates. Despite the excellent activity of new antimicrobials, rational antibiotic policy must be thoroughly followed, supported by complementary treatments and strict anti-epidemic precautions.
format Online
Article
Text
id pubmed-10451955
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104519552023-08-26 Carbapenem-Resistant Klebsiella pneumoniae in COVID-19 Era—Challenges and Solutions Ficik, Jozef Andrezál, Michal Drahovská, Hana Böhmer, Miroslav Szemes, Tomáš Liptáková, Adriána Slobodníková, Lívia Antibiotics (Basel) Article The COVID-19 era brought about new medical challenges, which, together with nosocomial bacterial infections, resulted in an enormous burden for the healthcare system. One of the most alarming nosocomial threats was carbapenem-resistant Klebsiella pneumoniae (CRKP). Monitoring CRKP incidence and antimicrobial resistance globally and locally is vitally important. In a retrospective study, the incidence of CRKP in the pre-COVID-19 period (2017–2019) and the COVID-19 pandemic (2020–2022) was investigated in the Central Military Hospital in Ružomberok, Slovak Republic. The relative incidence of CRKP significantly increased during the COVID-19 period—by 4.8 times, from 0.18 to 0.76%. At the same time, 47% of CRKP-positive patients also had COVID-19. Twenty-six KPC and sixty-nine NDM-producing isolates were identified. CRKPs isolated in the year 2022 were submitted to whole genome sequencing, and their susceptibility was tested to cefiderocol, ceftazidime–avibactam, imipenem–relebactam and meropenem–vaborbactam, with excellent results. KPC-producing isolates were also highly susceptible to colistin (92%). The NDM isolates revealed lower susceptibility rates, including only 57% colistin susceptibility. ST-307 prevailed in KPC and ST-11 in NDM isolates. Despite the excellent activity of new antimicrobials, rational antibiotic policy must be thoroughly followed, supported by complementary treatments and strict anti-epidemic precautions. MDPI 2023-08-04 /pmc/articles/PMC10451955/ /pubmed/37627705 http://dx.doi.org/10.3390/antibiotics12081285 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ficik, Jozef
Andrezál, Michal
Drahovská, Hana
Böhmer, Miroslav
Szemes, Tomáš
Liptáková, Adriána
Slobodníková, Lívia
Carbapenem-Resistant Klebsiella pneumoniae in COVID-19 Era—Challenges and Solutions
title Carbapenem-Resistant Klebsiella pneumoniae in COVID-19 Era—Challenges and Solutions
title_full Carbapenem-Resistant Klebsiella pneumoniae in COVID-19 Era—Challenges and Solutions
title_fullStr Carbapenem-Resistant Klebsiella pneumoniae in COVID-19 Era—Challenges and Solutions
title_full_unstemmed Carbapenem-Resistant Klebsiella pneumoniae in COVID-19 Era—Challenges and Solutions
title_short Carbapenem-Resistant Klebsiella pneumoniae in COVID-19 Era—Challenges and Solutions
title_sort carbapenem-resistant klebsiella pneumoniae in covid-19 era—challenges and solutions
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451955/
https://www.ncbi.nlm.nih.gov/pubmed/37627705
http://dx.doi.org/10.3390/antibiotics12081285
work_keys_str_mv AT ficikjozef carbapenemresistantklebsiellapneumoniaeincovid19erachallengesandsolutions
AT andrezalmichal carbapenemresistantklebsiellapneumoniaeincovid19erachallengesandsolutions
AT drahovskahana carbapenemresistantklebsiellapneumoniaeincovid19erachallengesandsolutions
AT bohmermiroslav carbapenemresistantklebsiellapneumoniaeincovid19erachallengesandsolutions
AT szemestomas carbapenemresistantklebsiellapneumoniaeincovid19erachallengesandsolutions
AT liptakovaadriana carbapenemresistantklebsiellapneumoniaeincovid19erachallengesandsolutions
AT slobodnikovalivia carbapenemresistantklebsiellapneumoniaeincovid19erachallengesandsolutions